#1 Clinical Trials Search in Europe

Clostridia, Cluster Xiva, Strain Relative Blautia Sp001304935, Live

Recent clinical trials are investigating the use of VE303, a novel drug containing live bacterial strains, for the prevention of recurrent Clostridioides difficile infection (CDI). This article summarizes the key aspects of these trials, including the drug’s composition, study design, and potential benefits for patients suffering from this challenging condition.

Table of Contents

What is VE303?

VE303 is an innovative medical treatment being developed to combat Clostridioides difficile infection (CDI), a serious bacterial infection that affects the digestive system. It is currently undergoing clinical trials to evaluate its effectiveness and safety[1].

VE303 is a capsule that contains a carefully selected mixture of beneficial bacteria. These bacteria are live and belong to various strains and species, including[1]:

  • Clostridia, cluster XIVA, strain relative Clostridium_Q symbiosum
  • Clostridia, cluster XIVA, strain relative Enterocloster bolteae
  • Clostridia, cluster XIVA, strain relative Sellimonas intestinalis
  • Clostridia, cluster IV, strain relative Flavonifractor plautii
  • Clostridia, cluster XIVA, strain relative Blautia sp001304935
  • Bacilli, cluster XVII, strain relative Clostridium_AQ innocuum
  • Clostridia, cluster XIVA, strain relative Dorea_A longicatena
  • Clostridia, cluster IV, strain relative Anaerotruncus colihominis

How Does VE303 Work?

VE303 is a type of treatment known as a live biotherapeutic product (LBP). It works by introducing beneficial bacteria into the gut to help restore a healthy balance of microorganisms[1]. In the case of Clostridioides difficile infection, these good bacteria can help fight off the harmful C. difficile bacteria and prevent them from causing further damage to the intestines.

What Condition Does VE303 Treat?

VE303 is being developed to treat Clostridioides difficile infection (CDI). CDI is a serious condition that causes inflammation of the colon, leading to symptoms such as severe diarrhea, fever, and abdominal pain. It often occurs after a person has taken antibiotics, which can disrupt the normal balance of bacteria in the gut[1].

Specifically, VE303 is being studied for its potential to prevent recurrent CDI. Recurrent CDI is a significant problem, as some patients experience multiple episodes of the infection after initial treatment[1].

Clinical Trial Details

VE303 is currently being evaluated in a Phase 3 clinical trial called the RestoratiVE303 Study. This study is designed to assess how well VE303 works in preventing recurrent CDI compared to a placebo. Here are some key details about the trial[1]:

  • The study is randomized, double-blind, and placebo-controlled, which means participants are randomly assigned to receive either VE303 or a placebo, and neither the participants nor the researchers know who is receiving which treatment.
  • Participants take VE303 or placebo orally for 14 consecutive days.
  • The main goal is to compare the rate of CDI recurrence at 8 weeks between those who received VE303 and those who received the placebo.
  • The study also looks at CDI recurrence rates at 12 and 24 weeks, as well as the safety of VE303.
  • Researchers will measure how well VE303 bacteria colonize the gut and how long they persist.
  • The study will assess the impact of VE303 on participants’ quality of life and daily CDI symptoms.

Potential Benefits

If successful, VE303 could offer several potential benefits for patients with recurrent CDI[1]:

  • Reduced risk of CDI recurrence
  • Improved quality of life
  • Fewer CDI-related symptoms
  • A more balanced and healthy gut microbiome
  • An alternative to traditional antibiotic treatments, which can sometimes contribute to recurrent CDI

Safety Considerations

As with any new medical treatment, safety is a crucial consideration. The clinical trial is designed to carefully monitor for any side effects or adverse events. Some important safety points to note[1]:

  • The study excludes people with certain medical conditions or a history of severe CDI complications to ensure participant safety.
  • Participants are closely monitored throughout the study period.
  • The trial includes a follow-up period to assess long-term safety.
  • People with known allergies to any ingredients in VE303 are not eligible to participate in the study.

Conclusion

VE303 represents an exciting new approach to treating recurrent Clostridioides difficile infection. By using a carefully selected mix of beneficial bacteria, it aims to restore balance to the gut microbiome and prevent the recurrence of this challenging infection. While the results of the clinical trial are still pending, VE303 offers hope for a potentially safer and more effective treatment option for those suffering from recurrent CDI[1].

Aspect Details
Study Drug VE303 (live bacterial strains in capsule form)
Target Condition Recurrent Clostridioides difficile infection (CDI)
Study Design Randomized, double-blind, placebo-controlled Phase 3 study
Primary Objective Compare CDI recurrence rate at Week 8 between VE303 and placebo groups
Treatment Duration 14 days of oral VE303 or placebo after standard antibiotic therapy
Follow-up Period 24 weeks
Key Eligibility Age ≥12 years (≥18 in some countries), laboratory-confirmed CDI, prior CDI history
Main Outcomes CDI recurrence rates, safety profile, quality of life measures

FAQ

  • What is VE303 and how does it work? VE303 is a capsule containing live bacterial strains designed to prevent recurrent Clostridioides difficile infection (CDI). It works by helping to restore a healthy balance of gut bacteria, which can be disrupted by CDI and antibiotic treatments.
  • Who is eligible to participate in the VE303 clinical trial? The trial includes patients aged 12 and older (18+ in some countries) who have had a laboratory-confirmed CDI episode and at least one prior CDI occurrence within the last 6 months. There are also specific criteria for older patients and those with certain risk factors.
  • How long does the VE303 treatment last? In the clinical trial, VE303 or placebo is administered orally for 14 consecutive days following standard antibiotic treatment for CDI.
  • What are the main goals of the VE303 clinical trial? The primary goal is to compare the CDI recurrence rate at 8 weeks between participants treated with VE303 and those given a placebo. Secondary objectives include assessing safety, long-term efficacy, and quality of life improvements.
  • Are there any notable exclusion criteria for the trial? Yes, some key exclusions include pregnant or breastfeeding individuals, those with chronic diarrhea unrelated to CDI, people with certain gastrointestinal conditions, and those who have recently used probiotics or other live bacterial products for CDI treatment.

Ongoing Clinical Trials on Clostridia, Cluster Xiva, Strain Relative Blautia Sp001304935, Live

  • Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +8

Glossary

  • Clostridioides difficile infection (CDI): A bacterial infection that causes diarrhea and can be life-threatening. It often occurs after using antibiotics that disrupt the normal balance of gut bacteria.
  • Recurrent CDI: When CDI symptoms return after initial treatment, usually within 8 weeks. This can happen multiple times and is challenging to treat.
  • VE303: An investigational drug containing live bacterial strains designed to prevent recurrent CDI by restoring a healthy gut microbiome.
  • Standard of Care (SoC) antibiotic therapy: The current best practice treatment for CDI, typically involving antibiotics like vancomycin or fidaxomicin.
  • Placebo: An inactive substance that looks like the real drug but has no therapeutic effect, used as a control in clinical trials.
  • Randomized, double-blind study: A type of clinical trial where participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the researchers know who is receiving which treatment.
  • Microbiome: The collection of all microorganisms, including bacteria, that live in or on the human body, particularly in the gut.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the study treatment.
  • Quality of life measures: Tools used to assess how a medical condition or treatment affects a person's overall well-being and ability to function in daily life.

References

  1. http://clinicaltrials.eu/trial/study-on-ve303-for-preventing-recurrent-c-difficile-infection-in-patients/